Novo Nordisk A/S

New York Stock Exchange
Back to all articles
Bearish -65

Novo Nordisk shares in hot water after disappointing trial

📉 Novo Nordisk shares fell 8.6% in U.S. trading and 7.5% in Denmark after the ZEUS trial failed its main goal.

💊 The experimental drug Ziltivekimab successfully lowered inflammation markers but did not reduce major adverse cardiovascular events like heart attacks or strokes.

📊 The trial of over 6,300 patients resulted in a hazard ratio of 0.99, showing no benefit over placebo for preventing heart events.

⚠️ Patients taking Ziltivekimab experienced more serious infections than those on the placebo group during the study.

💸 Novo Nordisk expects to record a non-cash impairment charge in Q3 2026 related to the failed trial.

📈 The company maintained its full-year 2026 adjusted operating profit outlook despite the asset write-down.

🔬 Two other late-stage trials, HERMES and ARTEMIS, continue with results expected in the first half of 2027.

⚖️ Novo Nordisk faces a shareholder lawsuit regarding disclosures about its CagriSema weight-loss trial design.

🏥 The drug is being tested in patients with heart failure and those recovering from acute heart attacks in future studies.

📉 This failure complicates Novo's strategy to grow beyond Wegovy and Ozempic as Eli Lilly gains market share.

Bullish Signals
  • The company confirmed that the trial failure will not change its 2026 adjusted operating profit outlook, keeping near-term earnings intact.
  • Ziltivekimab successfully demonstrated its intended biological effect by lowering inflammation markers in patients.
  • Two additional late-stage trials (HERMES and ARTEMIS) are still ongoing with results expected in the first half of 2027.
  • The core diabetes and obesity business remains the primary driver of revenue, which is not threatened by this specific trial failure.
  • Management reaffirmed its commitment to cardiovascular disease research despite the setback in the ZEUS trial.
Risk Factors
  • The ZEUS trial failed its main goal, causing shares to drop 8.6% and signaling a major disappointment for investors.
  • The drug showed no reduction in major adverse cardiovascular events, recording a hazard ratio of 0.99 compared to placebo.
  • Patients on Ziltivekimab suffered from higher rates of serious infections than those on the placebo group.
  • Novo Nordisk will take a non-cash impairment charge in Q3 2026, reducing the recorded value of the asset.
  • The failure weakens Novo's cardiovascular pipeline outside of its weight-loss drugs, narrowing its competitive edge over Eli Lilly.
  • Analysts had widely expected Ziltivekimab to deliver heart benefits and reach billions in annual sales, which is now on hold.
  • The company faces a shareholder lawsuit regarding previous trial disclosures, adding legal pressure to the operational setback.
  • This failure removes one of the key paths Novo was counting on to widen its lead over rival Eli Lilly in the heart health sector.
Full Analysis
Novo Nordisk (NVO) shares dropped sharply on July 31 after its experimental heart drug, Ziltivekimab, failed to meet the primary endpoint of the large-scale ZEUS late-stage trial. The Danish pharmaceutical giant had been counting on this cardiovascular asset to serve as a second growth engine alongside its dominant weight-loss and diabetes franchises, Wegovy and Ozempic. Investors reacted swiftly to the disappointment, with U.S.-listed shares falling 8.6% and Danish shares declining approximately 7.5% in early trading. The ZEUS trial involved over 6,300 patients with atherosclerotic cardiovascular disease, chronic kidney disease, and ongoing inflammation. While the drug successfully lowered inflammation markers by blocking the IL-6 protein, it failed to reduce the rate of major adverse cardiovascular events such as heart attacks, strokes, or cardiovascular death. The trial recorded a hazard ratio of 0.99, indicating that patients on the drug faced nearly the same risk as those on a placebo. Additionally, the treatment was associated with higher rates of serious infections compared to the placebo group. Following the failure, Novo Nordisk announced it will record a non-cash impairment charge in its third-quarter 2026 financial report to write down the value of the asset. Despite this setback, the company maintained its adjusted operating profit outlook for 2026. The drug remains under investigation in two other late-stage trials, HERMES and ARTEMIS, which target patients with heart failure and those recovering from acute heart attacks, respectively. Results for these subsequent studies are expected in the first half of 2027. The trial result exacerbates Novo Nordisk's recent challenges as it attempts to expand beyond its core GLP-1 business while facing competition from Eli Lilly. The company faces a shareholder lawsuit regarding previous trial disclosures and must now determine if future cardiovascular programs can succeed where ZEUS failed. Management stated that the failure does not alter their commitment to treating cardiovascular disease, but the setback removes a key path for widening the company's lead over rivals in the heart health sector.